Characterization of SIV in the oral cavity and in vitro inhibition of SIV by Rhesus Macaque Saliva

AIDS Research and Human Retroviruses

Volumn 26, Issue 8, 2010, Pages 901-911

  Thomas, Jessica S ^a   Lacour, Nedra ^a   Kozlowski, Pamela A ^a   Nelson, Steve ^a   Bagby, Gregory J ^a   Amedee, Angela M ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; VIRUS RNA;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ARTICLE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; IN VITRO STUDY; MOUTH CAVITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SALIVA; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTIVITY; VIRUS INHIBITION; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MALE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS LOAD;

ADAPTIVE IMMUNITY; ANIMALS; DISEASE MODELS, ANIMAL; GENOTYPE; HUMANS; IMMUNITY, INNATE; MACACA MULATTA; MALE; RNA, VIRAL; SALIVA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

EID: 77955650405     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0235     Document Type: Article

References (41)

1. Hall HI, Song R, Rhodes P, et al.: Estimation of HIV incidence in the United States. JAMA 2008;300(5):520-529.
2. Campo J, Perea MA, del Romero J, Cano J, Hernando V, and Bascones A: Oral transmission of HIV, reality or fiction: An update. Oral Dis 2006;12(3):219-228.
3. Moutsopoulos NM, Greenwell-Wild T, and Wahl SM: Differential mucosal susceptibility in HIV-1 transmission and infection. Adv Dent Res 2006;19(1):52-56.
4. Liuzzi G, Clementi M, Bagnarelli P, Valenza A, Cataldo PT, and Piazza M: Analysis of HIV-1 load in blood, semen and saliva: Evidence for different viral compartments in a crosssectional and longitudinal study. AIDS 1996;10(14):F51-F56.
5. Rothenberg RB, Scarlett M, del Rio C, Reznik D, and ODaniels C: Oral transmission of HIV. AIDS 1998;12(16): 2095-2105.
6. Shugars DC, Slade GD, Patton LL, and Fiscus SA: Oral and systemic factors associated with increased levels of human immunodeficiency virus type 1 RNA in saliva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89(4): 432-440.
7. Shugars DC and Wahl SM: The role of the oral environment in HIV-1 transmission. J Am Dent Assoc 1998;129(7): 851-858.
8. Freel SA, Williams JM, Nelson JAE, et al.: Characterization of human immunodeficiency virus type 1 in saliva and blood plasma by V3-specific heteroduplex tracking assay and genotype analyses. J Virol 2001;75(10):4936- 4940.
9. Freel SAFS, Pilcher CD, Menezes P, Giner J, Patrick E, Lennox JL, Hicks CB, Eron JJ Jr, and Shugars DC: Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. AIDS 2003;17(14):2025-2033.
10. Shugars DC: Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis 1999;179(Suppl 3):S431-S435.
11. Fultz PN: Components of saliva inactivate human immunodeficiency virus. Lancet 1986;2(8517):1215.
12. Shine N, Konopka K, and Duzgunes N: The anti-HIV-1 activity associated with saliva. J Dent Res 1997;76(2):634-640.
13. Nagashunmugam T, Davis C, Kennedy S, Goldstein LT, and Malamud D: Human submandibular saliva specifically inhibits HIV type 1. AIDS Res Hum Retroviruses 1997;13(5): 371-376.
14. Nagashunmugam T MD, Davis C, Abrams WR, and Friedman HM: Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. J Infect Dis 1998;178:1635-1641.
15. Malamud D, Berthold P, Roth E, and Friedman HM: Human submandibular saliva aggregates HIV. AIDS Research and Human Retroviruses. 1993;9:633-637.
16. Challacombe SJ and Sweet SP: Oral mucosal immunity and HIV infection: Current status. Oral Dis. 2002;8(2):55-62.
17. Lackner AA and Veazey RS: Current concepts in AIDS pathogenesis: Insights from the SIV/macaque model. Annu Rev Med. 2007;58:461-476.
18. Whitney JB, Luedemann C, Bao S, et al.: Monitoring HIV vaccine trial participants for primary infection: Studies in the SIV/macaque model. AIDS 2009;23(12):1453-1460.
19. Kozlowski PA, Lynch RM, Patterson RR, Cu-Uvin S, Flanigan TP, and Neutra MR: Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J Acquir Immune Defic Syndr 2000;24(4):297-309.
20. Bagby GJ, Zhang P, Purcell JE, Didier PJ, and Nelson S: Chronic binge ethanol consumption accelerates progression of simian immunodeficiency virus disease. Clin Exp Res 2006;30(10):1781-1790.
21. Amedee A, Rychert J, Lacour N, Fresh L, and Ratterree M: Viral and immunological factors associated with breast milk transmission of SIV in rhesus macaques. Retrovirology 2004;1(1):17.
22. Rychert J, Lacour N, and Amedee AM: Genetic analysis of simian immunodeficiency virus expressed in milk and selectively transmitted through breastfeeding. J Virol 2006; 80(8):3721-3731.
23. Krowicka H, Robinson JE, Clark R, Hager S, Broyles S, and Pincus SH: Use of tissue culture cell lines to evaluate HIV antiviral resistance. AIDS Res Hum Retroviruses 2008;24(7): 957-967.
24. Kestler HW 3rd, Naidu YN, Kodama T, et al.: Use of infectious molecular clones of simian immunodeficiency virus for pathogenesis studies. J Med Primatol 1989;18(3-4): 305-309.
25. Kodama T, Burns DP, Kestler HW 3rd, Daniel MD, and Desrosiers RC: Molecular changes associated with replication of simian immunodeficiency virus in human cells. J Med Primatol 1990;19(3-4):431-437.
26. Cole KS, Rowles JL, Jagerski BA, et al.: Evolution of envelope- specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 1997;71(7):5069-5079.
27. Montefiori DC: Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protocall Immunol 2005;Chapter 12:Unit 12 11.
28. Mascola JR, DSouza P, Gilbert P, et al.: Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005; 79(16):10103-10107.
29. Polonis VR, Brown BK, Rosa Borges A, et al.: Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 2008;375(2):315-320.
30. Cory AH, Owen TC, Barltrop JA, and Cory JG: Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991;3(7):207-212.
31. Kozlowski PA, Chen D, Eldridge JH, and Jackson S: Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals. AIDS Res Hum Retroviruses 1994;10(7):813-822.
32. Wang SW, Kozlowski PA, Schmelz G, et al.: Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. J Virol 2000;74(22):10514-10522.
33. Shugars DC, Alexander AL, Fu K, and Freel SA: Endogenous salivary inhibitors of human immunodeficiency virus. Arch Oral Biol 1999;44(6):445-453.
34. Cohen MS, Shugars DC, and Fiscus SA: Limits on oral transmission of HIV-1. Lancet 2000;356(9226):272.
35. Choi WS, Collignon C, Thiriart C, et al.: Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity. J Virol 1994;68(9):5395-5402.
36. Borda JT, Alvarez X, Kondova I, et al.: Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis. Am J Pathol 2004; 165(6):2111-2122.
37. Follis KE, Trahey M, LaCasse RA, and Nunberg JH: Continued utilization of CCR5 coreceptor by a newly derived Tcell line-adapted isolate of human immunodeficiency virus type 1. J Virol 1998;72(9):7603-7608.
38. Cole KS, Alvarez M, Elliott DH, et al.: Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology 2001;290(1):59-73.
39. Hirbod T, Reichard C, Hasselrot K, et al.: HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals. Curr HIV Res 2008;6(1):28-33.
40. Hasselrot K, Saberg P, Hirbod T, et al.: Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. AIDS 2009;23(3):329-333.
41. Farquhar C, VanCott T, Bosire R, et al.: Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya. Clin Exp Immunol 2008;153(1):37-43.